文献速递其他结缔组织病

系统性硬化症中的功能性自身抗体:自体干细胞移植的影响及其与临床结局的相关性

Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

本研究分析43例接受自体干细胞移植的系统性硬化症患者,其中31例移植后结局良好(第1组),12例无应答或复发(第2组)。移植后抗拓扑异构酶I抗体和抗AT1R抗体(ELISA法)显著下降,但功能性抗AT1R抗体活性未受移植影响;移植前抗拓扑异构酶I抗体高反应性与不良结局相关,而刺激性抗AT1R抗体仅见于结局良好组。

要点

  • 移植前70%患者ELISA检出抗拓扑异构酶I抗体,51%检出抗AT1R抗体,所有抗拓扑异构酶I抗体均抑制酶功能。
  • 移植后抗拓扑异构酶I抗体和抗AT1R抗体(ELISA法)显著下降,但功能性抗AT1R抗体活性未受移植影响。
  • 移植前抗拓扑异构酶I抗体高反应性与移植后不良结局相关,刺激性抗AT1R抗体仅见于结局良好组。

核心结论

  • 功能性抗AT1R抗体反应性未受自体干细胞移植影响,而抗拓扑异构酶I抗体在移植后下降。
  • 抗拓扑异构酶I抗体在所有情况下均抑制酶功能,支持拓扑异构酶I抗原/抗体系统在系统性硬化症中具有致病作用的假说。
  • 移植前高抗拓扑异构酶I反应性与移植后不良病程相关,而刺激性抗AT1R抗体的存在与良好病程相关。

研究设计与样本

  • 分析43例接受自体干细胞移植的系统性硬化症患者,其中31例移植后结局良好(第1组),12例无应答或复发(第2组)。
  • 采用ELISA法和基于表达AT1R的Huh7细胞系的发光测定法(LA)检测患者血清中的抗AT1R抗体和抗拓扑异构酶I抗体,检测时间点为移植前和移植后(4-217个月,中位28个月)。
  • 还分析了抗拓扑异构酶I抗体抑制酶功能的能力。

主要发现

  • 移植前70%的系统性硬化症患者ELISA检出抗拓扑异构酶I抗体,51%检出抗AT1R抗体。
  • 所有抗拓扑异构酶I抗体均抑制拓扑异构酶I酶功能。
  • 在LA中,40%的患者具有刺激性抗AT1R抗体,12%具有抑制性抗AT1R抗体。
  • 移植后抗拓扑异构酶I抗体和抗AT1R抗体(ELISA法)反应性显著下降。
  • 移植前第2组患者的抗拓扑异构酶I抗体反应性显著高于第1组(P < 0.001),而两组间ELISA法检测的抗AT1R抗体无差异;LA检测的刺激性抗AT1R抗体仅局限于第1组患者。

关键数值与推荐

  • 移植前第2组抗拓扑异构酶I抗体反应性显著高于第1组(P < 0.001)。
  • 移植前70%患者ELISA检出抗拓扑异构酶I抗体,51%检出抗AT1R抗体;LA中40%具有刺激性抗AT1R抗体,12%具有抑制性抗AT1R抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of autologous stem cell transplantation (aSCT) on functional antibodies (abs) to the angiotensin II type-1-receptor (AT1R) and topoisomerase-I (topo-I) in SSc-patients and to analyse their prognostic relevance. MATERIAL AND METHODS: Forty-three SSc-patients in whom aSCT was performed were analysed. Thirty-one patients had a favourable outcome after aSCT (group 1), 12 patients showed no response or relapse (group 2). Patients' sera were tested for anti-AT1R and anti-topo-I antibodies by ELISA and in a luminometric assay (LA) using AT1R-expressing Huh7-cells for inhibitory or stimulatory anti-AT1R antibodies before and after aSCT (4-217 months, median 28 months). Anti-topo-I antibodies were also analysed for their capacity to inhibit enzyme function. RESULTS: A total of 70% of the SSc patients had anti-topo-I- and 51% anti-AT1R antibodies in the ELISA before aSCT. In all instances, anti-topo-I antibodies inhibited topo-I-enzyme function. In the LA, 40% had stimulatory and 12% inhibitory anti-AT1R antibodies. Anti-topo-I- and anti-AT1R-reactivity (ELISA) significantly decreased after aSCT. Before aSCT, anti-topo-I-reactivity was significantly higher in group 2 patients than in group 1 patients (P < 0.001), while there was no difference between both groups for anti-AT1R antibodies detected by ELISA. Stimulatory anti-AT1R antibodies detected by LA were confined to group 1-patients. CONCLUSIONS: Reactivity of functionally active anti-AT1R antibodies was not influenced by aSCT, while anti-topo-I antibodies decreased after aSCT. The fact that anti-topo-I antibodies inhibited enzyme function in all instances supports the hypothesis of a pathogenetic role of the topo-I antigen/antibody-system in SSc. High anti-topo-I reactivity before aSCT was associated with an unfavourable, presence of stimulatory anti-AT1R antibodies with a favourable course after aSCT.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Bankamp L, Preuß B, Pecher AC, et al. Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome. Rheumatology (Oxford). 2023. PMID: 36222553. doi:10.1093/rheumatology/keac549

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。